Selecting the most appropriate biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) for initial or subsequent treatment in patients with rheumatoid arthritis is a challenge for clinicians. Reliable evidence indicating the superiority of any of the DMARDs is rare. However, the evidence to date may be analyzed to point clinicians to the most appropriate choices for a given patient. Join Dr. Marc D. Cohen as he considers the factors and discusses the relevant studies that permit comparison between available DMARDs. Throughout the discussion you will find videos, journal articles, and other sources to enhance understanding of relevant issues.